Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
PRNewswire (Thu, 4-Jun 4:37 PM ET)
INOVIO to Participate in Upcoming Scientific and Investor Conferences
PRNewswire (Thu, 28-May 8:05 AM ET)
PRNewswire (Thu, 21-May 4:05 PM ET)
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
PRNewswire (Wed, 13-May 4:05 PM ET)
INOVIO’s Presence at Major Scientific Conferences Shines Spotlight on Its DNA Medicine Strategy
Market Chameleon (Fri, 8-May 7:23 AM ET)
INOVIO to Participate in Upcoming Scientific Conferences
PRNewswire (Fri, 8-May 8:05 AM ET)
INOVIO to Report First Quarter Financial Results on May 13, 2026
PRNewswire (Fri, 1-May 4:05 PM ET)
PRNewswire (Tue, 7-Apr 2:52 PM ET)
Globe Newswire (Tue, 7-Apr 12:00 PM ET)
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Inovio Pharmaceuticals trades on the NASDAQ stock market under the symbol INO.
As of June 24, 2026, INO stock price declined to $1.12 with 906,563 million shares trading.
INO has a beta of 0.94, meaning it tends to be less sensitive to market movements. INO has a correlation of 0.01 to the broad based SPY ETF.
INO has a market cap of $92.15 million. This is considered a Micro Cap stock.
Last quarter Inovio Pharmaceuticals reported $0 in Revenue and -$.28 earnings per share. This fell short of revenue expectation by $-250,000 and exceeded earnings estimates by $.04.
In the last 3 years, INO traded as high as $14.75 and as low as $1.03.
The top ETF exchange traded funds that INO belongs to (by Net Assets): VTI, VXF, IWC, QQQS.
INO has underperformed the market in the last year with a return of -42.0%, while the SPY ETF gained +24.3%. In the last 3 month period, INO fell short of the market, returning -30.4%, while SPY returned +13.0%. However, in the most recent 2 weeks INO has outperformed the stock market by returning +1.8%, while SPY returned +0.5%.
INO support price is $1.08 and resistance is $1.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INO shares will trade within this expected range on the day.